An oncologist’s perspective on measuring success in the clinic

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Even though cancer center and health system leaders know this deep down, most also find no way better to measure the success of programs and providers than the inscrutable Relative Value Unit, or RVU.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Steven R. Grossman, MD, PhD
Professor of medicine, cancer physician in chief, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine of USC
Table of Contents

YOU MAY BE INTERESTED IN

In this week's episode of The Cancer Letter Podcast, editor and publisher Paul Goldberg, and associate editor Jacquelyn Cobb revisit two of last week’s most-read stories: the growing recognition that early-onset colorectal cancer requires a new diagnostic mindset, and the life and legacy of Maura Gillison, the scientist whose discovery that most head and neck cancers are driven by HPV transformed the field. 
For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.
Steven R. Grossman, MD, PhD
Professor of medicine, cancer physician in chief, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine of USC

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login